Fecal microbiota transplantation (FMT) showed a 60.5% overall response rate at day 28 in steroid-refractory acute graft-versus-host disease (aGvHD) patients.
GI involvement was the primary indication for FMT, addressing gut dysbiosis linked to aGvHD pathophysiology.
More than half of patients experienced related adverse events, yet no unexpected safety signals emerged.
Significant secondary benefit included a 54.5% decolonization rate of antibiotic-resistant bacteria.
